论文部分内容阅读
目的观察甘露聚糖肽联合尿激酶在治疗恶性胸腔积液中的疗效。方法将58例恶性胸腔患者随机分组,治疗组30例,对照组28例。对照组常规顺铂治疗,治疗组采用甘露聚糖肽联合尿激酶腔内给药治疗。结果治疗组有效率(83.3%),高于对照组的60.7%,差异有统计学意义(P<0.05);治疗组体力状态KPS评分好转率(73.3%),高于对照组的35.7%,差异有统计学意义(P<0.005)。治疗组4例患者治疗期间出现发热,为低热,3例患者出现轻度胸痛,及时服用解热镇痛药物后,病情得到了有效治疗。治疗组患者的肝功能、肾功能、血常规均正常,没有1例出现出血、积液包裹、积液分隔的情况,也没有出现毒副反应或过敏反应,而对照组出现多例不良反应,如发热、胸痛、骨髓抑制、胃肠道反应等。结论甘露聚糖肽联合尿激酶胸腔内注射治疗恶性胸腔积液疗效显著,不良反应小,易为患者所接受,明显提高患者生活质量,值得临床推广应用。
Objective To observe the efficacy of mannan peptide and urokinase in the treatment of malignant pleural effusion. Methods 58 patients with malignant pleural cavity were randomly divided into treatment group (30 cases) and control group (28 cases). Control group conventional cisplatin treatment, the treatment group using mannan peptide combined with urokinase intracavitary treatment. Results The effective rate (83.3%) in the treatment group was higher than that in the control group (60.7%) (P <0.05). The improving rate of KPS score in the treatment group was 73.3%, which was higher than that in the control group (35.7% The difference was statistically significant (P <0.005). Four patients in the treatment group experienced fever during treatment, mild fever, mild chest pain in three patients and prompt treatment with antipyretic and analgesic drugs. In the treatment group, liver function, renal function and blood routine were all normal. No bleeding, effusion, or fluid separation occurred in one patient. No adverse reaction or allergic reaction occurred in the treatment group, and many adverse reactions occurred in the control group. Such as fever, chest pain, bone marrow suppression, gastrointestinal reactions. Conclusion Mannan peptide injection combined with urokinase intrapleural injection of malignant pleural effusion has obvious curative effect and small adverse reaction, which is easy to be accepted by patients and significantly improves the quality of life of patients. It is worthy of clinical application.